Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 27

Cited In for PubMed (Select 18614864)

1.

Impact of human immunodeficiency virus type-1 sequence diversity on antiretroviral therapy outcomes.

Langs-Barlow A, Paintsil E.

Viruses. 2014 Oct 20;6(10):3855-72. doi: 10.3390/v6103855.

2.

Low-frequency NNRTI-resistant HIV-1 variants and relationship to mutational load in antiretroviral-naïve subjects.

Gupta S, Lataillade M, Kyriakides TC, Chiarella J, St John EP, Webb S, Moreno EA, Simen BB, Kozal MJ.

Viruses. 2014 Sep 16;6(9):3428-37. doi: 10.3390/v6093428.

3.

First line treatment response in patients with transmitted HIV drug resistance and well defined time point of HIV infection: updated results from the German HIV-1 seroconverter study.

Zu Knyphausen F, Scheufele R, Kücherer C, Jansen K, Somogyi S, Dupke S, Jessen H, Schürmann D, Hamouda O, Meixenberger K, Bartmeyer B.

PLoS One. 2014 May 1;9(5):e95956. doi: 10.1371/journal.pone.0095956. eCollection 2014.

4.

Prevalence and evolution of low frequency HIV drug resistance mutations detected by ultra deep sequencing in patients experiencing first line antiretroviral therapy failure.

Vandenhende MA, Bellecave P, Recordon-Pinson P, Reigadas S, Bidet Y, Bruyand M, Bonnet F, Lazaro E, Neau D, Fleury H, Dabis F, Morlat P, Masquelier B.

PLoS One. 2014 Jan 27;9(1):e86771. doi: 10.1371/journal.pone.0086771. eCollection 2014.

5.

Improved detection of rare HIV-1 variants using 454 pyrosequencing.

Larsen BB, Chen L, Maust BS, Kim M, Zhao H, Deng W, Westfall D, Beck I, Frenkel LM, Mullins JI.

PLoS One. 2013 Oct 2;8(10):e76502. doi: 10.1371/journal.pone.0076502. eCollection 2013.

6.

No clinically significant drug-resistance mutations in HIV-1 subtype C-infected women after discontinuation of NRTI-based or PI-based HAART for PMTCT in Botswana.

Souda S, Gaseitsiwe S, Georgette N, Powis K, Moremedi D, Iketleng T, Leidner J, Moffat C, Ogwu A, Lockman S, Moyo S, Mmalane M, Musonda R, Makhema J, Essex M, Shapiro R.

J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):572-7. doi: 10.1097/QAI.0b013e31829308f8.

7.

Clinical implications of HIV-1 minority variants.

Li JZ, Kuritzkes DR.

Clin Infect Dis. 2013 Jun;56(11):1667-74. doi: 10.1093/cid/cit125. Epub 2013 Feb 27.

8.

Characterizing the emergence and persistence of drug resistant mutations in HIV-1 subtype C infections using 454 ultra deep pyrosequencing.

Bansode V, McCormack GP, Crampin AC, Ngwira B, Shrestha RK, French N, Glynn JR, Travers SA.

BMC Infect Dis. 2013 Jan 30;13:52. doi: 10.1186/1471-2334-13-52.

9.
10.

Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients.

Theys K, Deforche K, Vercauteren J, Libin P, van de Vijver DA, Albert J, Asjö B, Balotta C, Bruckova M, Camacho RJ, Clotet B, Coughlan S, Grossman Z, Hamouda O, Horban A, Korn K, Kostrikis LG, Kücherer C, Nielsen C, Paraskevis D, Poljak M, Puchhammer-Stockl E, Riva C, Ruiz L, Liitsola K, Schmit JC, Schuurman R, Sönnerborg A, Stanekova D, Stanojevic M, Struck D, Van Laethem K, Wensing AM, Boucher CA, Vandamme AM; SPREAD-programme.

Retrovirology. 2012 Oct 3;9:81. doi: 10.1186/1742-4690-9-81.

11.

Viral quasispecies evolution.

Domingo E, Sheldon J, Perales C.

Microbiol Mol Biol Rev. 2012 Jun;76(2):159-216. doi: 10.1128/MMBR.05023-11. Review.

12.

Low-cost ultra-wide genotyping using Roche/454 pyrosequencing for surveillance of HIV drug resistance.

Dudley DM, Chin EN, Bimber BN, Sanabani SS, Tarosso LF, Costa PR, Sauer MM, Kallas EG, O'Connor DH.

PLoS One. 2012;7(5):e36494. doi: 10.1371/journal.pone.0036494. Epub 2012 May 4.

13.

Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infection.

Stekler JD, Ellis GM, Carlsson J, Eilers B, Holte S, Maenza J, Stevens CE, Collier AC, Frenkel LM.

PLoS One. 2011;6(12):e28952. doi: 10.1371/journal.pone.0028952. Epub 2011 Dec 16.

14.

Applications of next-generation sequencing technologies to diagnostic virology.

Barzon L, Lavezzo E, Militello V, Toppo S, Palù G.

Int J Mol Sci. 2011;12(11):7861-84. doi: 10.3390/ijms12117861. Epub 2011 Nov 14. Review.

15.

Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infection.

Metzner KJ, Leemann C, Di Giallonardo F, Grube C, Scherrer AU, Braun D, Kuster H, Weber R, Guenthard HF.

PLoS One. 2011;6(7):e21734. doi: 10.1371/journal.pone.0021734. Epub 2011 Jul 6.

16.

Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants.

Gianella S, Delport W, Pacold ME, Young JA, Choi JY, Little SJ, Richman DD, Kosakovsky Pond SL, Smith DM.

J Virol. 2011 Aug;85(16):8359-67. doi: 10.1128/JVI.02582-10. Epub 2011 Jun 1.

17.

Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects.

Codoñer FM, Pou C, Thielen A, García F, Delgado R, Dalmau D, Álvarez-Tejado M, Ruiz L, Clotet B, Paredes R.

PLoS One. 2011;6(5):e19461. doi: 10.1371/journal.pone.0019461. Epub 2011 May 13.

18.

Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis.

Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, Kozal MJ, Hullsiek KH, Balduin M, Jakobsen MR, Geretti AM, Thiebaut R, Ostergaard L, Masquelier B, Johnson JA, Miller MD, Kuritzkes DR.

JAMA. 2011 Apr 6;305(13):1327-35. doi: 10.1001/jama.2011.375. Review.

19.

Minority variants of drug-resistant HIV.

Gianella S, Richman DD.

J Infect Dis. 2010 Sep 1;202(5):657-66. doi: 10.1086/655397. Review.

20.

Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast Asia.

Hoare A, Kerr SJ, Ruxrungtham K, Ananworanich J, Law MG, Cooper DA, Phanuphak P, Wilson DP.

PLoS One. 2010 Jun 8;5(6):e10981. doi: 10.1371/journal.pone.0010981.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk